Authors: | Kollmeier, M. A.; Zelefsky, M. J. |
Article Title: | What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer? |
Abstract: | This Practice Point commentary discusses the paper by Horwitz and colleagues, which reported the long-term results of the RTOG 92-02 trial in which patients with locally advanced, node-negative prostate cancer who were treated with neoadjuvant-concurrent hormone ablation therapy and external beam radiation therapy (70 Gy) were subsequently randomized to receive either no further androgen deprivation or long-term (2-year) goserelin therapy. The results at 10 years confirm biochemical and clinical outcome benefits with the use of long-term androgen deprivation therapy for patients treated with conventional-dose radiotherapy. How these results should best be incorporated into dose-escalated radiotherapeutic approaches remains unclear, however, and this issue requires further investigation. |
Keywords: | cancer survival; overall survival; androgen; clinical trial; advanced cancer; cancer growth; cancer radiotherapy; disease free survival; radiation dose; distant metastasis; prostate cancer; prostatic neoplasms; goserelin; gastrointestinal toxicity; radiation dose fractionation; androgen antagonists; long term care; brachytherapy; short survey; external beam radiotherapy; antineoplastic agents, hormonal; androgen therapy; androgens |
Journal Title: | Nature Clinical Practice Urology |
Volume: | 5 |
Issue: | 11 |
ISSN: | 1743-4270 |
Publisher: | Nature Publishing Group |
Date Published: | 2008-01-01 |
Start Page: | 584 |
End Page: | 585 |
Language: | English |
DOI: | 10.1038/ncpuro1217 |
PUBMED: | 18813218 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 17 November 2011" - "Source: Scopus" |